Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.7 (plasmin)
 9,023 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Normal IgG and purified IgG proteins of all 4 subclasses were digested with plasmin. As expected, IgG3 proteins were highly susceptible to degradation. Usually, activation with streptokinase resulted in faster and more accentuated degradation, but normal IgG was more intensely degraded by nonactivated plasmin. The presence of plasmin activators in IgG preparation might account for this observation.
 ...
PMID:The sensitivity to plasmin digestion of human IgG proteins of different heavy chain subclasses. 14 52

Today almost all IgG preparations for intravenous use (IVIG) fulfill the basic requirements for a preparation given intravenously (sterility, pyrogenicity, antibody content but also anticomplementary activity, etc.). However, there are still marked differences among such preparations caused by the method of preparation: (1) Enzymatically treated IVIGs (by pepsin and plasmin) have a shorter biologic half-time and a disturbed IgG subclass composition; (2) in chemically treated IVIGs (beta-propiolactone, reduced or sulfonated IgGs) the IgG3 subclass is lacking and some of the Fc-related functions are altered; and (3) the IVIGs purified by anion exchangers are poor in the IgG4 subclass. The three main preparations sold in the United States (Gamimune N, Gammagard and Sandoglobulin) belong to the nonmodified preparations and, with the exception of the IgG subclass representation, show similar Fab- and Fc-related properties (antibody content, interaction with Fc receptors on monocytes, phagocytosis-promoting activity, etc.) In none of these preparations, an elevated level of undesired contaminants (prekallikrein activator, irregular anti-erythrocyte antibodies) are found.
 ...
PMID:Differences among available immunoglobulin preparations for intravenous use. 245 10

In two of four non-enzymatically treated gamma-globulin preparations C Immunoglobulin Schura, Immunoglobulin SRK), the distribution of IgG subclasses was found to be close to that of normal human serum. In two other preparations (sulphonated and beta-propiolactone-treated) IgG3 was not detectable by means of appropriate antiserum. The IgG residual portion of plasmin-treated gamma-globulin was enriched in IgG2, while IgG3 was absent. In affinity chromatography on protein A Sepharose, IgG3 in the unbound and IgG1, IgG2 and IgG4 in the bound fractions were found in Immunoglobulins Schura and SRK. In the sulphonated preparation no IgG was found in the unbound fraction, while IgG1, IgG2 and IgG4 were eluted from the bound fraction. In beta-propiolactone-treated gamma-globulin IgG1, IgG2 and IgG4 were present in both fractions. The testing of reactivity of IgG subclasses with Staphylococcus protein A can supply important information about the state of the Fc part in immunoglobulin preparations.
 ...
PMID:IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A. 615 36

Three major components of the plasminogen activators (PA)/plasmin system are synthesized physiologically in glomeruli, and can be involved in glomerular proteolysis and extracellular matrix metabolism: tissue-type PA (tPA), urokinase (uPA) and PA inhibitor type 1 (PAI-1). To explore the possible role of a dysregulation of the plasmin protease system in the development and progression of lupus-like glomerulonephritis, we studied the expression of the renal plasmin protease components during the course of the disease, either acute, induced by IgG3 monoclonal cryoglobulins, or chronic, occurring spontaneously in three different lupus-prone mice: (NZBxNZW)F1, BXSB and MRL-lpr/lpr. RNase protection assays and in situ hybridizations revealed a marked glomerular induction of PAI-1 mRNA abundance without any significant changes in renal tPA and uPA mRNA levels in the two different types of lupus-like glomerulonephritis. The overexpression of PAI-1 mRNA occurred in parallel with a significant decrease in glomerular tPA-catalyzed enzymatic activity as determined by zymographic analysis. In addition, a concomitant increase in glomerular expression of transforming growth factor beta 1 (TGF-beta 1) mRNA was observed. The demonstration of a close correlation between the PAI-1 and TGF-beta 1 mRNA levels and the severity of lupus-like glomerular lesions suggests that a pertubation of the glomerular PA/PAI balance, resulting from a marked TGF-beta 1-mediated induction of PAI-1 gene expression, plays an important role in the progression of lupus-like glomerular lesions, leading to glomerulosclerosis.
 ...
PMID:Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. 854 2